Trust Co. of Vermont Sells 2,355 Shares of Celgene Co. (NASDAQ:CELG)

Trust Co. of Vermont cut its stake in Celgene Co. (NASDAQ:CELG) by 3.8% in the second quarter, HoldingsChannel.com reports. The fund owned 59,139 shares of the biopharmaceutical company’s stock after selling 2,355 shares during the period. Trust Co. of Vermont’s holdings in Celgene were worth $5,467,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Archford Capital Strategies LLC grew its position in Celgene by 277.8% during the first quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 200 shares during the period. Investors Research Corp bought a new stake in Celgene during the first quarter valued at approximately $28,000. Weaver Consulting Group bought a new stake in Celgene during the first quarter valued at approximately $29,000. Alera Investment Advisors LLC grew its position in Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 167 shares during the period. Finally, Creative Financial Designs Inc. ADV grew its position in Celgene by 1,968.8% during the first quarter. Creative Financial Designs Inc. ADV now owns 331 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 315 shares during the period. Hedge funds and other institutional investors own 74.77% of the company’s stock.

NASDAQ:CELG traded up $0.45 during trading hours on Tuesday, hitting $93.33. 252,079 shares of the stock traded hands, compared to its average volume of 3,928,913. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 1.97. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $98.97. The stock has a market capitalization of $65.94 billion, a P/E ratio of 12.28, a price-to-earnings-growth ratio of 0.44 and a beta of 1.46. The firm has a 50 day moving average of $93.22.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The business had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.22 billion. During the same quarter in the previous year, the firm earned $2.16 earnings per share. The company’s revenue for the quarter was up 15.4% on a year-over-year basis. As a group, research analysts forecast that Celgene Co. will post 9.96 earnings per share for the current year.

Several analysts recently issued reports on CELG shares. Cowen restated a “hold” rating and set a $102.00 target price on shares of Celgene in a research report on Tuesday, July 30th. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Saturday. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a research report on Friday, May 3rd. ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Finally, Mizuho restated a “buy” rating and set a $103.00 target price on shares of Celgene in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Celgene currently has an average rating of “Hold” and an average target price of $94.81.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What is a balanced fund?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.